Covalent inhibitors of KRASG12C (KRASi) hold considerable progress for tumors driven by this oncogene yet early studies suggest rapid mechanisms of adaptive resistance that appear cell type dependent.
Public description: Human NSCLC cell lines were chronically treated with sotorasib, RMC-4998, or a combination of sotorasib and RMC-4550 to generate resistant models. The cells were then subjected to
KRAS is the most frequently mutated oncogene found in pancreatic, colorectal, and lung cancers. Although it has been challenging to identify targeted therapies for cancers harboring KRAS mutations, on
